<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02222194</url>
  </required_header>
  <id_info>
    <org_study_id>ASTER 3</org_study_id>
    <nct_id>NCT02222194</nct_id>
  </id_info>
  <brief_title>The Value of Surgical Mediastinal Staging in Clinical N1 Lung Cancer</brief_title>
  <acronym>ASTER3</acronym>
  <official_title>Assessment of Surgical Mediastinal sTaging in cN1 Lung canceR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnny Moons</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gasthuisberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In case of PET or CT based cN1 (suspected) NSCLC, ESTS guidelines propose mediastinal staging&#xD;
      by echo-endoscopy OR mediastinoscopy. Recent data show a sensitivity of less than 50% for&#xD;
      echo-endoscopy to detect N2 disease in cN1 NSCLC patients, while prevalence of mediastinal&#xD;
      nodal disease was 24% (unpublished data Aster II).2 The investigators plan to perform a&#xD;
      prospective multicentric observational study to measure the sensitivity of mediastinal&#xD;
      staging by video-assisted mediastinoscopy (VAM) in cN1 operable and resectable (suspected)&#xD;
      NSCLC patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Few reports in the literature evaluated the final pathological stage distribution of patients&#xD;
      with resectable and operable non-small cell lung cancer (NSCLC) with clinical stage cN1.&#xD;
      These retrospective series demonstrated that patients with computed tomography (CT) based cN1&#xD;
      often had clinically occult mediastinal lymph node metastases (N2/3 disease). Hishida et al.&#xD;
      reported that 30% of 143 patients with cN1 were diagnosed N2/3 by mediastinoscopy3. Watanabe&#xD;
      et al. reported that 37% of 168 patients with cN1 were diagnosed N2/3 by mediastinoscopy 4.&#xD;
      Adding FDG-positron emission tomography (PET) to CT might enable the detection of N2/3&#xD;
      disease among these cN1 patients, but negative PET findings do not necessarily exclude N2/3&#xD;
      disease. Kim et al reported that 19,2 % of 99 patients with cN1, in whom cN2 was ruled out by&#xD;
      PET-CT scan, were found to have pathologic N2 disease at pulmonary resection with mediastinal&#xD;
      lymph node dissection.5 In conclusion, 20-30% of patients with cN1 nodes on imaging, and&#xD;
      normal sized FDG-negative mediastinal lymph nodes on CT and PET have malignant involvement in&#xD;
      their mediastinal nodes.&#xD;
&#xD;
      The ACCP guidelines state that invasive preoperative mediastinal staging should be performed&#xD;
      in these cN1 patients 6. The updated ESTS guidelines recommend mediastinal staging by&#xD;
      echo-endoscopic or mediastinoscopy.1 Non-randomized trials suggested the potential of linear&#xD;
      endosonography for mediastinal staging 7-9. However, the patients with cN1 disease form only&#xD;
      a minority in these studies. A recently performed prospective ASTER 2 trial (N=100) showed a&#xD;
      sensitivity of echo-endoscopic for mediastinal staging of 38% (ITT analysis), while the&#xD;
      prevalence of mediastinal nodal disease was 24% (unpublished data Aster 2) 2. The conclusion&#xD;
      made by ASTER 2 is that a negative endosonography must be followed by a VAM. However, the&#xD;
      investigators consider such double approach not cost-effective in a setting with N2&#xD;
      prevalence &lt;30%. Therefore, it seems reasonable to perform a VAM instead of an endosonography&#xD;
      in cN1 patients, which is one of the proposed strategies in the recent ESTS guidelines.1&#xD;
      However, there is no prospective study to date that assessed the sensitivity, NPV and&#xD;
      accuracy of VAM in a well-defined group of cN1 patients.&#xD;
&#xD;
      Several publications have demonstrated a lobe-specific mediastinal nodal drainage for upper&#xD;
      versus lower lobe NSCLC. Shapiro et al conclude that in early lung cancer, including cN1&#xD;
      disease, lobe-specific mediastinal dissection is warranted 10. However, in this study the&#xD;
      only patient with a positive subcarinal node, upper lobe tumour, and negative superior&#xD;
      mediastinal nodes had positive N1 nodes. To the investigators knowledge there is no study&#xD;
      focussing on mediastinal nodal dissemination patterns in cN1 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">May 30, 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of VAM</measure>
    <time_frame>at surgery (VAM)</time_frame>
    <description>Sensitivity (%) of surgical mediastinal staging by video-assisted mediastinoscopy in clinical N1; true positives (TP) = cN1 and pN1 - false negatives (FP) = cN1 and pN2/3; sensitivity is calculated as TP / (TP+FN)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of N2/3 disease after VAM</measure>
    <time_frame>at surgery (VAM)</time_frame>
    <description>% of patients with cN1 disease who show pN2/3 disease after VAM</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">105</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>VAM</arm_group_label>
    <description>Patients with operable and resectable cT1-2-selected T3 cN1cM0 NSCLC undergo VAM for mediastinal lymph node staging. After VAM, patients without tissue proof of N2/3 disease at surgical staging undergo a VATS or thoracotomy with systematic lymph node dissection during the same anaesthesia or at a later stage.&#xD;
Sensitivity, NPV and accuracy of staging with VAM will be calculated. Provided N2 lymph node metastases are proven by VAM the patient goes off study protocol and can further be assessed/treated according to local clinical practice.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with operable and resectable cT1-2- selectedT3 cN1 (suspected) NSCLC. (selected T3&#xD;
        = intraparenchymal tumour &gt;7cm or T3 chest wall or T3 additional nodule, excluding&#xD;
        mediastinal invasion or invasion of the main bronchus &lt; 2cm from the carina)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        (Suspected) NSCLC Medical operable and surgical resectable cT1, cT2 selected cT3 (i.e.&#xD;
        intraparenchymal tumour &gt;7cm, T3 chest wall, or T3 based on additional nodule in the lobe&#xD;
        of the primary tumour) cN1 based on CT or PET 18 years or older Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        History of mediastinoscopy No integrated FDG PET/CT available No videomediastinoscopy&#xD;
        available EBUS/EUS for mediastinal staging of present N1 disease cN2: mediastinal nodes&#xD;
        enlarged on CT or Pet positive invasion of mediastinal pleura invasion of phrenic nerve&#xD;
        invasion of parietal pericardium tumour in main bronchus less than 2cm form the main carina&#xD;
        cT4 cM1 former therapy for lung cancer (chemotherapy, radiotherapy, surgery) technical&#xD;
        contraindication for videomediastinoscopy ( eg extreme kyphosis, cutaneous tracheostomy,&#xD;
        extreme goiter) pregnancy inability to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Decaluw√©, MD</last_name>
    <role>Study Director</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aix-Marseille University &amp; Hospitals System of Marseille (AP-HM)</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ELK Berlin Chest Hospital</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert-Ludwigs-University Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholisches Klinikum Koblenz</name>
      <address>
        <city>Koblenz</city>
        <zip>56073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholisches Klinikum, Thoraxchirurgie</name>
      <address>
        <city>Koblenz</city>
        <zip>56073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Mutua Terrassa</name>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic; Barcelona University</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Division of Thoracic Surgery</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University, Cerrahpasa Medical Faculty</name>
      <address>
        <city>Istanbul</city>
        <zip>81080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>August 18, 2014</study_first_submitted>
  <study_first_submitted_qc>August 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2014</study_first_posted>
  <last_update_submitted>July 22, 2017</last_update_submitted>
  <last_update_submitted_qc>July 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gasthuisberg</investigator_affiliation>
    <investigator_full_name>Johnny Moons</investigator_full_name>
    <investigator_title>Data Manager / Clinical Trial Coordinator</investigator_title>
  </responsible_party>
  <keyword>Lung cancer</keyword>
  <keyword>Surgery</keyword>
  <keyword>Videomediastinoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

